NANOSONICS LIMITED — AGM Information 2021

Nov 18, 2021

==> picture [250 x 141] intentionally omitted <==

Infection Prevention. For Life. ANNUAL GENERAL MEETING 2021

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 1

A C K N O W L E D G E M E N T O F C O U N T R Y

We acknowledge the traditional owners of the various lands in which we meet virtually today and pay respects to all Aboriginal Elders, past and present, and acknowledge today’s Aboriginal communities who are the custodians of these lands.

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 2

B O A R D O F D I R E C T O R S

==> picture [109 x 108] intentionally omitted <==

Maurie Stang Non-Executive Chairman

==> picture [107 x 108] intentionally omitted <==

David Fisher Non-Executive Director

==> picture [106 x 106] intentionally omitted <==

Steven Sargent Non-Executive Director, Deputy Chairman and Lead Independent Director

==> picture [104 x 103] intentionally omitted <==

Marie McDonald Non-Executive Director

==> picture [107 x 106] intentionally omitted <==

Michael Kavanagh CEO and President

==> picture [107 x 107] intentionally omitted <==

Geoff Wilson Non-Executive Director

==> picture [106 x 106] intentionally omitted <==

Lisa McIntyre Non-Executive Director

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 3

O N L I N E A T T E N D E E S – Q U E S T I O N P R O C E S S

When the Question function is available, the Q&A icon will appear at the top of the app.

==> picture [47 x 40] intentionally omitted <==

To send in a question, simply click in the ‘Ask a question’ box, type your question and the press the send arrow Your question will be sent immediately for review

==> picture [305 x 172] intentionally omitted <==

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 4

O N L I N E A T T E N D E E S – V O T I N G P R O C E S S

When the poll is open, the vote will be accessible by selecting the voting icon at the top of the screen

==> picture [46 x 47] intentionally omitted <==

To vote simply select the direction in which you would like to cast your vote, the selected option will change colour.

There is no submit or send button, your selection is automatically recorded.

==> picture [357 x 202] intentionally omitted <==

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 5

==> picture [250 x 141] intentionally omitted <==

Infection Prevention. For Life. ANNUAL GENERAL MEETING 2021

CHAIRMAN’S ADDRESS

Maurie Stang, Chairman

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 6

Our people, our advantage

TOTAL EMPLOYEES ENDING FY21 339 (+9% VS. FY20)

% STRONGLY ALIGNED TO COMPANY 94 PURPOSE % KNOW HOW THEIR WORK CONTRIBUTES 93 TO COMPANY GOALS

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 7

1Compound Annual Growth Rate 2Science, Technology, Engineering, Mathematics

G R O W I N G O P P O R T U N I T I E S

M A R K E T S

INCREASED TAM IN NORTH AMERICA

50% growth in trophon TAM (to 60,000 units), driven by strong ultrasound growth.

IMPROVING FUNDAMENTALS FOR ADOPTION IN EMEA Increase in guidelines and associated Nanosonics investment in the region.

Driving trophon® business growth

EXPANDING OUR BUSINESS IN ASIA PACIFIC Strengthening fundamentals in Japan, and established local presence in China.

P R O D U C T S

==> picture [44 x 95] intentionally omitted <==

==> picture [40 x 34] intentionally omitted <==

INVESTMENTS IN INNOVATION

Continued investments in product expansion strategy with $17.2 million in R&D directed across multiple projects.

NANOSONICS AUDITPRO[TM]

Launched new digital product platform delivering a unique new digital workflow compliance management system.

NEXT TECHNOLOGY PLATFORM – CORIS[®]

Advanced our next infection prevention technology platform focussed on one of the most significant issues in instrument reprocessing today – flexible endoscope cleaning.

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021

8

F I V E C O R E A R E A S O F R & D F O C U S

==> picture [384 x 232] intentionally omitted <==

==> picture [399 x 157] intentionally omitted <==

----- Start of picture text -----

INVESTMENT IN R&D
Global, $m
$17.2
$15.6  11% vs. FY20
$11.4
$9.9
$9.5
FY17 FY18 FY19 FY20 FY21
----- End of picture text -----

==> picture [69 x 36] intentionally omitted <==

All research and new product development programs involve inherent risks and uncertainties which can impact commercialisation timelines.

STRATEGIC CAPABILITIES

Core R&D

Sustaining engineering

External technology evaluation Nanosonics Investments

Nanosonics Limited | Annual General Meeting 2021 9

C O N T I N U E D C O M M I T M E N T T O S U S T A I N A B I L I T Y A N D S O C I A L R E S P O N S I B I L I T Y

==> picture [178 x 247] intentionally omitted <==

SUSTAINABILITY HIGHLIGHTS[1]

~88 k Patients protected daily from the risk of cross-contamination Developed sustainable Supply Chain initiatives

Introduced Executive Risk Management Committee Strengthened IT, Privacy & Cybersecurity protections

Zero major work health and safety incidents

~$44k in funds raised through charitable initiatives

DIVERSITY & INCLUSION

We value all aspects of diversity fostering an inclusive workplace for all to fulfil their . potential

N A T I O NAL I T I E S ~ R E P RE SE NT E D 29

F E M AL E % G E NDER R A T I O 41

CONTINUED ENVIRONMENTAL COMMITMENT

==> picture [197 x 118] intentionally omitted <==

==> picture [286 x 107] intentionally omitted <==

==> picture [69 x 36] intentionally omitted <==

1For full details, refer to the Nanosonics 2021 Sustainability Report

F E M AL E S I N % S T E M[2] R O LE S 42

I N T E RNS/ GRA DUA T E P ROGRA MS 14

2Science, Technology, Engineering, Mathematics 3National Greenhouse Accounts Factors (NGAF)

Nanosonics Limited | Annual General Meeting 2021 10

L E A D E R S H I P

Nanosonics has a highly experienced and dedicated team of professionals leading the development and implementation of our strategic growth agenda.

BOARD OF DIRECTORS

MAURIE STEVEN MICHAEL MARIE STANG SARGENT KAVANAGH MCDONALD

DAVID LISA GEOFF FISHER MCINTYRE WILSON

EXECUTIVE TEAM

MICHAEL MCGREGOR KEN RONAN DAVID RENEE STEVEN ROD JODI KAVANAGH GRANT SHAW WRIGHT MORRIS SALABERRY FARRUGIA LOPEZ SAMPSON

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 11

==> picture [250 x 141] intentionally omitted <==

Infection Prevention. For Life. ANNUAL GENERAL MEETING 2021

CEO & PRESIDENT’S ADDRESS

Michael Kavanagh, CEO and President

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 12

F Y 2 1 K E Y H I G H L I G H T S

A year of ongoing achievement with a significant recovery in H2 - to pre COVID growth momentum levels

==> picture [780 x 301] intentionally omitted <==

----- Start of picture text -----

CONSUMABLES/
INSTALLED BASE TOTAL REVENUE CAPITAL REVENUE SERVICE REVENUE
FY21 26,750 $103.1m $26.7m $76.4m
 %  % % cc1  % % cc1  % % cc1
13 3 (12 ) 11 (8 ) 9 (20 )
 % v s. H1  % v s. H1  % v s. H1  % v s. H1
H2 20 39 84 27
$60.0m $17.3m $42.7m
----- End of picture text -----

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021

1Constant currency removes the impact of foreign exchange rate movements to facilitate comparability of operational performance. This is done by converting the current year sales of entities that use currencies other than Australian dollars at the average rates that were applicable in the prior year.

13

“Nanosonics’ forwardlooking growth agenda remains very much intact with significant opportunities for growth of the trophon franchise as well as significant opportunities from the planned expanded product portfolio.” - Michael Kavanagh

OUR STRATEGIC PRIORITIES

Provide awareness TROPHON AS Support and education to establishment of highlight risks of STANDARD national cross contamination OF CARE guidelines. for all semi critical transducers.

Ensure Customers have a positive experience with all aspects of the product and brand.

Expand operations EXPAND across Asia Pacific & GEOGRAPHIC EMEA with trophon FOOTPRINT plus new products. Leverage Expand portfolio of Strategic technology PRODUCT infection prevention acquisitions in the platforms for EXPANSION solutions to address infection potential expanded unmet needs. prevention space. indications. Maintain strong Deliver operational INVEST financial position to efficiencies, scale TO GROW support growth. and leverage.

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Nanosonics Limited | Annual General Meeting 20212021 1414

TROPHON[®] OPPORTUNITY

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021

15

U L T R A S O U N D P R O C E D U R E S

There are over 150 procedures 1 that use ultrasound probes across many departments that risk contact with mucous membranes, non-intact skin and/or sterile tissue. E X A M P L E S ENDOCAVITARY UG[2] BIOPSY INTRAOPERATIVE NERVE BLOCKS WOUNDS Abdominal Duplex Biopsy of liver Intraoperative UG cervical nerve root UG burn patient Vascular (complete & neurosurgical procedures block assessment Biopsy of pancreas limited, transvaginal) Intraoperative UG tracer UG ankle block UG Focused Assessment Biopsy of pleural fluid Pregnancy scans injection with Sonography in UG femoral nerve block Biopsy of pulmonary Trauma (FAST) Chorionic Villus Sampling UG implantation of iodine lesions UG ophthalmic regional seeds UG focused diagnostic Transrectal scan anesthesia Biopsy of salivary gland echocardiography (e.g., UG percutaneous renal Transrectal prostate UG percutaneous cardiac resuscitation in Biopsy of sclerosing transplant biopsy biopsy peripheral nerve presence of trauma) mesenteritis UG transthoracic stimulation punctures

E X A M P L E S

• AND MANY MORE. . .

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021

2Ultrasound-guided

1Nanosonics analysis, SDMS guidelines, market reports

16

==> picture [780 x 470] intentionally omitted <==

----- Start of picture text -----

N O R T H A M E R I C A INSTALLED BASE OPPORTUNITY INSTALLED BASE
1 UNITS
60,000 23,480
There has been a significant increase in the trophon [®] 20,990
18,570
MARKET PENETRATION
15,620
opportunity in North America resulting from increased
12,400
estimate of Total Addressable Market, revised up to
60,0001 units from 40,000 units, reflecting growth in 39%
the ultrasound market over the last eight years. FY17 FY18 FY19 FY20 FY21
ULTRASOUND TROPHON TAM
INSTALLED BASE NORTH AMERICA [2]
UNIT E D ST AT E S
PRIOR

ESTIMATE 150k A detailed analysis of
40,000
UNITS the U.S. Ultrasound
market has revealed
that the total market
opportunity for
trophon is 50% larger
ESTIMATEREVISED  1 1
271k than previous
60,000
UNITS estimates.
----- End of picture text -----

==> picture [69 x 36] intentionally omitted <==

2Total Addressable Market Nanosonics Limited | Annual General Meeting 2021 updates to U.S. only.

17

1Nanosonics analysis based on updated ultrasound information commissioned by Nanosonics and an estimated trophon to ultrasound attachment rate. The North America market has been the focus of the TAM analysis undertaken.

S I G N I F I C A N T G L O B A L M A R K E T O P P O R T U N I T Y

==> picture [724 x 223] intentionally omitted <==

----- Start of picture text -----

Market Penetration
GLOBAL Installed base opportunity • Significant global growth opportunity.
• Increasing number of international guidelines requiring high level
1
19% disinfection (HLD) supporting growing international demand.
140,000 • Nanosonics expanding its footprint geographically both direct and
UNITS
through distribution.
N O R TH AMER IC A EU R O PE AN D MID D LE EAST ASIA PAC IFIC
Installed Base Opportunity Market Penetration Installed Base Opportunity Market Penetration Installed Base Opportunity Market Penetration
60,0001 40,0002 40,0002
UNITS 39% UNITS 4% UNITS 4%
UK ANZ
16% >75%
----- End of picture text -----

Strengthening Fundamentals

Strong Fundamentals

• Expanded geographical reach, strengthening fundamentals for adoption and growing awareness.

• Fundamentals for adoption strong with requirements for HLD in place.

• Expanded infrastructure with sales teams increasing in the UK and Germany, plus appointment of local clinical, marketing, regulatory, service, distributor partner engagement & people and culture leadership.

• trophon installed base over 23,480 and already in over 5,000 hospitals and clinics, including majority of luminary hospitals.

• Nanosonics has a direct sales operation of 74 people as well as partnerships with all leading ultrasound companies to drive ongoing adoption.

• A range of business models In place to support market requirements.

INSTALLED BASE

INSTALLED BASE

==> picture [454 x 89] intentionally omitted <==

----- Start of picture text -----

23,480
20,990 1,510
18,570
15,620 1,120
880
12,400 730
490
FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21
----- End of picture text -----

Strengthening Fundamentals

• Sales mainly in ANZ where market penetration is >75%.

• Japan market development strategy continues with local infrastructure established & distribution agreements in place with five key distributors.

• Finalised registration of a wholly owned subsidiary in China with regulatory submission being prepared.

• Assessment underway for further expansion across Asia Pacific.

INSTALLED BASE

==> picture [203 x 82] intentionally omitted <==

----- Start of picture text -----

1,760
1,610
1,480
1,390
1,270
FY17 FY18 FY19 FY20 FY21
----- End of picture text -----

==> picture [69 x 36] intentionally omitted <==

1Nanosonics analysis based on updated ultrasound information commissioned by Nanosonics and an estimated trophon to ultrasound attachment rate.

2Based on Nanosonics’ estimate from around 2011. While current data is not readily available for the Asia Pacific and Europe and Middle East regions, the Company considers that the ultrasound market has grown in these regions since the initial estimate of the Installed Base Opportunity was made.

Nanosonics Limited | Annual General Meeting 2021

18

C A P I T A L U P G R A D E S

==> picture [272 x 197] intentionally omitted <==

A significant capital upgrade potential exists in the installed base

GROWING OPPORTUNITY + units 6,500

AGED INSTALLED BASE UPGRADED TO-DATE[1] 8[%]

 Implemented trophon EPR end-of-life policies and notified customers.

 Upgrades is a key component of growth strategy for FY22.

==> picture [403 x 147] intentionally omitted <==

----- Start of picture text -----

9%
7%
6%
2%
1 yr 2 yrs 3 yrs 4 yrs 5 yrs 6 yrs 7 yrs 8 yrs 9 yrs 10+ yrs
----- End of picture text -----

G L O B A L I N S T A L L E D B A S E A G E D I S T R I B U T I O N A T J U N 2 0 2 1

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 19

1 Upgrades as a % of cumulative Installed Base 7 years or older

INSTALLED BASE OPPORTUNITY

INSTALLED BASE

E U R O P E A N D M I D D L E E A S T

Guidelines across Europe for ultrasound probe disinfection continue to strengthen with preferences for automated solutions that can be validated. This has supported installed base growth with significant ongoing growth potential.

==> picture [263 x 108] intentionally omitted <==

----- Start of picture text -----

40,000 UNITS 1,510
1,120
MARKET PENETRATION
880
730
UK 490
4% 16%
FY17 FY18 FY19 FY20 FY21
----- End of picture text -----

==> picture [102 x 33] intentionally omitted <==

----- Start of picture text -----

U LTR ASOU ND
R EPR O C ESSIN G
G U ID ELIN ES
----- End of picture text -----

==> picture [97 x 168] intentionally omitted <==

==> picture [95 x 195] intentionally omitted <==

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | | Annual General Meeting 20212021 20

N A N O S O N I C S P R E S E N C E I N E U R O P E A N D M I D D L E E A S T

We have broad presence and access to key markets to capitalise on the strengthening fundamentals across the region.

INVESTING FOR GROWTH EMEA EMPLOYEES Headcount, 2016-2021

==> picture [177 x 83] intentionally omitted <==

----- Start of picture text -----

 38% CAGR
2016 2021
----- End of picture text -----

==> picture [455 x 224] intentionally omitted <==

----- Start of picture text -----

MARKET ACCESS THROUGH DIRECT AND DISTRIBUTION CHANNELS
SWEDEN
FINLAND
NORWAY
ESTONIA
DENMARK RUSSIA
UNITED KINGDOM
IRELAND
----- End of picture text -----

NETHERLANDS GERMANY BELGIUM AUSTRIA

FRANCE SWITZERLAND ITALY SPAIN PORTUGAL

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 21

INSTALLED BASE OPPORTUNITY

INSTALLED BASE

A S I A P A C I F I C

We have ramped up our efforts to bring new markets online, with particular focus on the untapped potential in Japan, China and across the ASEAN countries.

==> picture [101 x 22] intentionally omitted <==

----- Start of picture text -----

40,000 UNITS
----- End of picture text -----

==> picture [264 x 93] intentionally omitted <==

----- Start of picture text -----

1,760
1,610
1,480
MARKET PENETRATION 1,390
1,270
ANZ
4% >75%
FY17 FY18 FY19 FY20 FY21
----- End of picture text -----

==> picture [37 x 16] intentionally omitted <==

----- Start of picture text -----

ANZ
----- End of picture text -----

The trophon technology is the standard of care in Australia and New Zealand

• Launched the trophon2 upgrade program with I-MED upgrading 200 trophon EPRs.

• Delivered education programs demonstrating the importance and requirements for high level disinfection for semi-critical probes in accordance with standards and guidelines.

• Continued to invest in our capabilities establishing an ANZ Customer Service Centre, including Clinical Application Specialists to ensure seamless and consistent Customer and Distributor experience.

==> picture [66 x 66] intentionally omitted <==

==> picture [60 x 16] intentionally omitted <==

----- Start of picture text -----

JAPAN
----- End of picture text -----

Built a solid foundation this year, as we work towards establishing local guidelines

• Conducted virtual education and training with relevant specialists, societies and distributors

• Continued to develop strong relationships with the ultrasound OEMs as distributors of trophon in Japan, as well as many subdistributors.

• Continue to build our direct team to drive market awareness and support our distributor partners.

==> picture [71 x 53] intentionally omitted <==

==> picture [57 x 16] intentionally omitted <==

----- Start of picture text -----

CHINA
----- End of picture text -----

Finalised Registration of Wholly Owned Foreign Enterprise (WOFE) 纳 安 诺 医 疗设备 （上海）有限公司 (translated to Nanosonics Medical Device (Shanghai) Co. Ltd.).

• Developing regulatory strategy.

• Appointed qualified local consultant in China to manage all local activity required for market entry.

==> picture [58 x 49] intentionally omitted <==

==> picture [62 x 16] intentionally omitted <==

----- Start of picture text -----

ASEAN
----- End of picture text -----

Received regulatory approval in Malaysia, Indonesia, Thailand and the Philippines

• Continued execution of our market entry strategy for ASEAN (Indonesia, Thailand, Malaysia, Philippines, Vietnam).

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 22

INVESTING FOR GROWTH RESEARCH & DEVELOPMENT

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 23

N E W P R O D U C T D E V E L O P M E N T

During the year, Nanosonics continued to invest in its product expansion strategy. R&D investment increased to $17.2m directed across multiple projects.

INVESTMENT IN R&D Global, $m

==> picture [23 x 8] intentionally omitted <==

----- Start of picture text -----

17.2
----- End of picture text -----

==> picture [346 x 174] intentionally omitted <==

----- Start of picture text -----

 % vs. FY20
15.6
11
11.4
9.9
9.5
FY17 FY18 FY19 FY20 FY21
----- End of picture text -----

Substantial investment made in new product development with important milestones met throughout the year towards our product expansion goals.

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 24

==> picture [461 x 540] intentionally omitted <==

I N T R O D U C I N G

Nanosonics Limited | Annual General Meeting 2021

25

==> picture [149 x 149] intentionally omitted <==

==> picture [539 x 74] intentionally omitted <==

INFECTION CONTROL WORKFLOW COMPLIANCE MANAGEMENT

Workflow compliance management tool that ensures customers consider the infection prevention requirements for all ultrasound procedures

Enhances clinical workflow

Practice standardization

Improves staff competency with the Spaulding Classification, reprocessing activities and probe usage. On-the-job education is built into everyday workflow.

Standardises ultrasound infection control compliance practices to improve risk management and quality control, delivering best practice.

Spaulding Patient MRN Probe

INFECTION CONTROL AT POINT-OF-CARE

DATA-LED INFECTION PREVENTION INSIGHTS

==> picture [128 x 110] intentionally omitted <==

Timely remediation and risk-minimization

Automated email notifications highlight noncompliance events for rapid risk assessment that enhances risk management for improved patient care.

Asset utilization and management overview Provides probe utilization dashboards so probe location and usage patterns can be tracked and compliance spot-checked.

Digitised traceability and record management Intuitive and information-rich dashboards providing actionable insights on infection control practices. Generates digital logbooks to help reduce operating costs and improve track and trace accuracy.

Supports accreditation

Streamlines your organisation’s compliance with National standards and evidence-based guidelines. It provides you with real-time risk notifications for easy course-correction and survey-ready ultrasound infection prevention compliance reports.

Compliance education

Uniquely sits with the ultrasound console at point of use, educating the user and enabling consistent incorporation of infection control considerations, as part of everyday clinician care.

Global best practice

Supports optimal patient care across your organisation by standardising best practice infection prevention decisions and managing staff compliance to Spaulding classification and your standard operating procedures (SOPs).

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 26

A U D I T P R O A N D T R O P H O N S Y N E R G I E S

AuditPro further enhances the trophon2 value proposition and competitive advantage.

N AN O SO NIC S AU D ITPR O[T M] H AS TH E PO TEN TIAL TO D R IVE…

trophon2 adoption EPR to trophon2 upgrades Consumables usage

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 27

OUR NEXT INSTRUMENT REPROCESSING PRODUCT PLATFORM

All research and new product development programs involve inherent risks and uncertainties which can impact commercialisation timelines.

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 28

O U R N E W P R O D U C T P L A T F O R M F O C U S

“more healthcareassociated outbreaks have been linked to contaminated endoscopes than to any other medical device”

U.S. Center for Disease Control (CDC)[1]

==> picture [141 x 179] intentionally omitted <==

A TOP 10 HEALTH TECHNOLOGY HAZARD

In 2018, the ECRI Institute listed “ failure to consistently and effectively reprocess flexible endoscopes ” as one

of the top 10 health technology hazards facing the Healthcare industry. In particular, the Institute drew attention

to “ The cleaning step , which is largely manual and technique-dependent. If biologic debris and other foreign material is not cleaned from the endoscope first, residual soil can harden, making subsequent disinfection ineffective.”

– ECRI Institute, 2018[2]

NANOSONICS CORIS[®] Transforming the cleaning of flexible endoscopes

AUTOMATED ENDOSCOPE CLEANING

The Nanosonics team have focussed on the complex technical challenges of flexible endoscope cleaning with the aim of developing a novel automated technology designed to revolutionise the cleaning process of flexible endoscopes.

1Guideline for Disinfection and Sterilization in Healthcare Facilities, U.S. CDC. Update: May 2019. 2Top 10 Health Technology Hazards for 2018, ECRI Institute, 2018. Nanosonics Limited | Annual General Meeting 2021 29 All research and new product development programs involve inherent risks and uncertainties which can impact commercialisation timelines.

F L E X I B L E E N D O S C O P E S

Reusable flexible endoscopes are highly sophisticated medical devices designed to enable advanced diagnostic and therapeutic interventions to diagnose and treat cancers and other life-threatening conditions. They incorporate advanced technology that gives physicians a sophisticated level of control in carrying out complex, minimally-invasive procedures and navigating challenging anatomical situations to deliver the highest level of patient care.

MANY SCOPE DESIGNS AND MODELS FOR A LARGE VARIETY OF COMPLEX CLINICAL PROCEDURES

COLONOSCOPY GASTROSCOPY E.R.C.P. ENTEROSCOPY ENDOSCOPIC BRONCHOSCOPY UROLOGY E.N.T. GYNAECOLOGY ULTRASOUND FLEXIBLE ENDOSCOPY MARKET[1] US, EU-5, AU MAJOR DRIVERS > m+ % Aging population 60 6 Increasing incidence of colorectal cancer ANNUAL ANNUAL Various national-level screening programs PROCEDURES GROWTH RATE

Nanosonics Limited | Annual General Meeting 2021 30

1Frost & Sullivan, Endoscope Reprocessing Systems and Software Solutions Market Assessment (US, W. Europe, Australia), 2018. All research and new product development programs involve inherent risks and uncertainties which can impact commercialisation timelines.

A R E C O G N I S E D R I S K

==> picture [780 x 399] intentionally omitted <==

----- Start of picture text -----

Flexible endoscopes have been associated with a high
frequency of outbreaks of healthcare-associated infections.
THERE ARE MANY WELL-DOCUMENTED INSTANCES OF…
INFECTION OUTBREAKS… …AND REPROCESSING ISSUES
COLONOSCOPES
GASTROSCOPES
BRONCHOSCOPES
UROLOGICAL SCOPES
E.R.C.P.
HUMAN FACTORS
BIOFILM
REPROCESSING FAILURE
. . .
…ACROSS MANY SCOPE TYPES INDICATING A SIGNIFICANT UNMET NEED WITH CURRENT METHODS.
----- End of picture text -----

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 31

All research and new product development programs involve inherent risks and uncertainties which can impact commercialisation timelines.

T H E P R O B L E M O F C L E A N I N G F L E X I B L E E N D O S C O P E S

==> picture [149 x 189] intentionally omitted <==

Challenges associated with manual cleaning, combined with reports of persistent contamination from biofilm despite routine cleaning, represents a significant unmet need and is a complex technical challenge that has existed for many years.

A 2021 study on gastroscopes revealed that extensive biofilm accumulated in the majority of air and water channels within 30 days of clinical use

despite routine cleaning .[1]

==> picture [400 x 190] intentionally omitted <==

----- Start of picture text -----

AIR WATER AIR/WATER
CHANNEL [1] CHANNEL [1] CHANNEL [2]
AIR/WATER SUCTION/BIOPSY
JUNCTION [1] CHANNEL [2]
----- End of picture text -----

HUMAN FACTORS Manual cleaning involves 55 to 200 individual steps, including brushing and flushing.

BIOFILM

Biofilm was detected in 83% of air/water channel components after 30-60 days of use[1] . Biofilm protects embedded microbes from HLD and requires physical cleaning methods to effectively be removed from channels.

SOPHISTICATED DESIGN

Intricate internal architecture has multiple interconnected channels with complex ports.

NARROW CHANNELS Many channels are so narrow or geometrically complex (e.g. air and water) that they are physically impossible to brush today.

Up to 200

steps

Up to 83%

Up to 9

channel openings Down to mm 1

In diameter

==> picture [72 x 32] intentionally omitted <==

1Primo, M.G.B., et al., 2021. Biofilm accumulation in new flexible gastroscope channels in clinical use. Infection Control & Hospital Epidemiology .

2Pajkos, A., et al., 2004. Is biofilm accumulation on endoscope tubing a contributor to the failure of cleaning & decontamination? Journal of Hospital Infection . All research and new product development programs involve inherent risks and uncertainties which can impact commercialisation timelines.

Nanosonics Limited | Annual General Meeting 2021 32

®

NANOSONICS CORIS

Nanosonics aims to address these challenges by replacing manual cleaning of endoscope channels with a novel automated technology that revolutionises the cleaning process , thereby reducing the risk of ineffective endoscope reprocessing and resulting patient infection.

Work continues to progress positively with the product development including the integration of a number of enhancements to the new platform. This work will be followed by external clinical assessment to support the regulatory submission. Nanosonics continues to engage with the US FDA to determine the necessary requirements to support a successful regulatory submission. The timing for commercial launch previously indicated is being revised and will be determined in due course dependent on the necessary technical, regulatory and operational milestones being met with the Company currently targeting the first commercial launch to occur in calendar 2023. Updates will be provided as material new information becomes available. The Company remains confident both in the ongoing progress of the development project, and importantly in the overall commercial opportunity for this transformational technology platform which it believes has the potential to become a new standard of care for endoscope cleaning.

Nanosonics Limited | Annual General Meeting 2021 33

All research and new product development programs involve inherent risks and uncertainties which can impact commercialisation timelines.

“Despite the inherent risks and uncertainties associated with COVID-19, we remain optimistic the improved market conditions will continue as vaccination numbers increase across all major markets.”

– Michael Kavanagh

FY22 BUSINESS OUTLOOK

(assuming the positive market recovery trends continue)

DOUBLE DIGIT REVENUE GROWTH

Increasing global installed base Increasing consumables usage across all regions Growth in EPR to trophon2 upgrades

Increasing capital (new IB and upgrades) in revenue mix GROSS PROFIT MARGIN >75%

OPERATING EXPENSES

Continued investment in our long-term strategic growth agenda

$90m

BEYOND FY22

TROPHON BUSINESS GROWTH

Global expansion of Trophon installed base and associated ecosystem Increasing upgrade momentum and conversions to trophon2 Critical new markets brought online, including Japan and China

NEW SOURCES OF REVENUE

Launch of Nanosonics AuditPro[TM] to new markets Further new product launches

INVESTMENT IN INNOVATION

Expanded product portfolio through internal product development and R&D Opportunities for strategic acquisitions and product licensing

LEADERSHIP IN INFECTION PREVENTION

==> picture [69 x 36] intentionally omitted <==

Ongoing investment in R&D, infrastructure, people and capabilities to drive our global growth strategy

Nanosonics Limited | Annual General Meeting 2021 3434

==> picture [250 x 141] intentionally omitted <==

Infection Prevention. For Life. ANNUAL GENERAL MEETING 2021

FORMAL BUSINESS

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 35

R E S O L U T I O N 1

Re-election of a director – Dr. David Fisher

==> picture [106 x 106] intentionally omitted <==

Resolution: That Dr. David Fisher, who retires as a Director pursuant to the Company’s Constitution and, being eligible, offers himself for re-election, be re-elected a Director.

Proxy votes received		Number	%
For	:	170,167,164	97.72
Against	:	3,279,127	1.88
Discretion	:	682,973	0.40
Abstained/Excluded	:	300,476	-

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 36

R E S O L U T I O N 2

Re-election of a director – Mr. Geoff Wilson

==> picture [105 x 106] intentionally omitted <==

Resolution: That Mr. Geoff Wilson, who retires as a Director pursuant to the Company’s Constitution and, being eligible, offers himself for re-election, be re-elected a Director.

Proxy votes received		Number	%
For	:	170,818,924	98.11
Against	:	2,598,880	1.49
Discretion	:	682,973	0.40
Abstained/Excluded	:	328,963	-

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 37

R E S O L U T I O N 3

Remuneration Report

Resolution:That the Remuneration Report for the	Proxy votes received		Number	%
financial year ended 30 June 2021 be adopted.	For	:	156,359,607	95.41
	Against	:	4,646,030	2.83
	Discretion	:	2,880,078	1.76
	Abstained/Excluded	:	10,544,025	-

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 38

R E S O L U T I O N 4

Issue of 30,010 Service Rights to the Chief Executive Officer and President, Mr. Michael Kavanagh, under the 2021 Short Term Incentive (2021 STI)

Resolution: That approval be given for all purposes under the Corporations Act 2001 (Cth) and the ASX Listing Rule 10.14 for the issue of 30,010 Service Rights to Mr Michael Kavanagh under the Nanosonics Omnibus Equity Plan ( Omnibus Plan ) in respect of the 2021 STI, on the terms set out in the Explanatory Notes accompanying this Notice of Meeting and in accordance with the Rules of the Omnibus Plan (as amended from time-to-time).

Proxy votes received		Number	%
For Against	: :	171,416,624 906,488	99.08 0.52
Discretion	:	699,844	0.40
Abstained/Excluded	:	1,406,784	-

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 39

R E S O L U T I O N 5

Issue of 190,114 Share Appreciation Rights and 132,760 Performance Rights to the Chief Executive Officer and President, Mr. Michael Kavanagh, under the 2021 Long-Term Incentive (2021 LTI)

Resolution: That approval be given for all purposes under the Corporations Act 2001 (Cth) and the ASX Listing Rule 10.14 for the issue of 190,114 Share Appreciation Rights and 132,760 Performance Rights to Mr Michael Kavanagh under the Omnibus Plan in respect of the 2021 LTI, on the terms set out in the Explanatory Notes accompanying this Notice of Meeting and in accordance with the Rules of the Omnibus Plan (as amended from time-to-time).

Proxy votes received		Number	%
For Against	: :	160,928,585 11,377,958	93.03 6.58
Discretion	:	681,018	0.39
Abstained/Excluded	:	1,442,179	-

Note: As indicated in the Notice of Meeting, the ASX 300 Industrials Index excludes companies in the energy and metal & mining industries. Nanosonics notes that the 2021 Remuneration Report includes references to the ASX300 Industrials Index incorrectly indicating that financial services are excluded from the ASX 300 Industrial Index.

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 40

R E S O L U T I O N 6

Adoption of New Constitution

Resolution: For the purposes of section 136(2) of the Corporations Act and for all other purposes, the Company’s constitution be amended by adopting in substitution for it, effective from the close of this meeting, the constitution tabled at the meeting and signed by the Chair for the purposes of identification.

Proxy votes received		Number	%
For Against	: :	171,020,765 161,083	98.24 0.09
Discretion	:	2,896,773	1.67
Abstained/Excluded	:	351,119	-

Note : Since the notice of meeting was issued, the Company has clarified that it is the Company’s intention to provide shareholders with ability to attend meetings in person, potentially in conjunction with the option to attend using Virtual Meeting Technology.

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 41

R E S O L U T I O N 7

Proportional Takeover Provisions in Constitution

Resolution: That the proportional takeover provisions in clause 14 of the proposed new Constitution referred to in Resolution 6, take effect for a period of three years commencing on the day this special Resolution is passed.

Proxy votes received		Number	%
For Against	: :	170,667,163 505,036	98.05 0.29
Discretion	:	2,886,413	1.66
Abstained/Excluded	:	371,128	-

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 42

O N L I N E A T T E N D E E S – Q U E S T I O N P R O C E S S

When the Question function is available, the Q&A icon will appear at the top of the app.

==> picture [47 x 40] intentionally omitted <==

To send in a question, simply click in the ‘Ask a question’ box, type your question and the press the send arrow Your question will be sent immediately for review

==> picture [305 x 172] intentionally omitted <==

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 43

O N L I N E A T T E N D E E S – V O T I N G P R O C E S S

When the poll is open, the vote will be accessible by selecting the voting icon at the top of the screen

==> picture [46 x 47] intentionally omitted <==

To vote simply select the direction in which you would like to cast your vote, the selected option will change colour.

There is no submit or send button, your selection is automatically recorded.

==> picture [357 x 202] intentionally omitted <==

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 44

O N L I N E A T T E N D E E S – Q U E S T I O N P R O C E S S

When the Question function is available, the Q&A icon will appear at the top of the app.

==> picture [47 x 40] intentionally omitted <==

To send in a question, simply click in the ‘Ask a question’ box, type your question and the press the send arrow Your question will be sent immediately for review

==> picture [305 x 172] intentionally omitted <==

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 45

DISCLAIMER

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

Certain information may relate to protected intellectual property rights owned by Nanosonics Limited (Nanosonics) and its subsidiaries (together the Group).

While due care has been taken in compiling the information based on the information available to Nanosonics at the date of this presentation material, neither Nanosonics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group.

The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement or estimate by any person (including Nanosonics). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Nanosonics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Group since the date of these materials.

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 46

==> picture [264 x 122] intentionally omitted <==

Nanosonics Limited 14 Mars Road, Lane Cove NSW 2066 Australia

T +61 2 8063 1600 E info@nanosonics.com.au www.nanosonics.com.au

ABN 11 095 076 896

==> picture [69 x 36] intentionally omitted <==

Nanosonics Limited | Annual General Meeting 2021 47